Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER THERAPY

AKTing on XPO1 inhibition in AML

Nature Cancer volume 3, pages 787–789 (2022)Cite this article

Subjects

Inhibition of XPO1-mediated nuclear export by selinexor represents a promising therapeutic strategy in acute myeloid leukemia. Because XPO1 is not specific for tumor-suppressive proteins, selinexor may also activate pro-oncogenic processes. A study now shows that inhibition of selinexor-induced, purinergic receptor–mediated AKT activation potentiates its anti-leukemic activity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Co-inhibition of AKT signaling potentiates the anti-leukemic effects of selinexor in AML.

References

  1. Hutten, S. & Kehlenbach, R. H. Trends Cell Biol. 17, 193–201 (2007).

    Article  CAS  Google Scholar 

  2. Tan, D. S., Bedard, P. L., Kuruvilla, J., Siu, L. L. & Razak, A. R. Cancer Discov. 4, 527–537 (2014).

    Article  CAS  Google Scholar 

  3. Kojima, K. et al. Blood 121, 4166–4174 (2013).

    Article  CAS  Google Scholar 

  4. Taylor, J. et al. Cancer Discov. 9, 1452–1467 (2019).

    Article  CAS  Google Scholar 

  5. Lin, K. H. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00394-x (2022).

    Article  PubMed  Google Scholar 

  6. Kasamon, Y. L. et al. Oncologist 26, 879–886 (2021).

    Article  CAS  Google Scholar 

  7. Azizian, N. G. & Li, Y. J. Hematol. Oncol. 13, 61 (2020).

    Article  Google Scholar 

  8. Etchin, J. et al. Leukemia 27, 66–74 (2013).

    Article  CAS  Google Scholar 

  9. Ranganathan, P. et al. Blood 120, 1765–1773 (2012).

    Article  CAS  Google Scholar 

  10. Fu, S. C., Huang, H. C., Horton, P. & Juan, H. F. Nucleic Acids Res. 41, D338–D343 (2013).

    Article  CAS  Google Scholar 

  11. Vadas, O. et al. Proc. Natl Acad. Sci. USA 110, 18862–18867 (2013).

    Article  CAS  Google Scholar 

  12. Degagné, E., Turgeon, N., Moore-Gagné, J., Asselin, C. & Gendron, F. P. FEBS J. 279, 2957–2965 (2012).

    Article  Google Scholar 

  13. Buck, M., Zhang, L., Halasz, N. A., Hunter, T. & Chojkier, M. EMBO J. 20, 6712–6723 (2001).

    Article  CAS  Google Scholar 

  14. Guo, J. et al. Purinergic Signal. https://doi.org/10.1007/s11302-022-09840-y (2022).

    Article  PubMed  Google Scholar 

  15. Palmer, A. C. & Sorger, P. K. Cell 171, 1678–1691.e1613 (2017).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine V - Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

    Stefanie Göllner & Carsten Müller-Tidow

  2. Molecular Medicine Partnership Unit, European Molecular Biology Laboratory and University of Heidelberg, Heidelberg, Germany

    Carsten Müller-Tidow

  3. National Center for Tumor Diseases, Heidelberg, Germany

    Carsten Müller-Tidow

Authors
  1. Stefanie Göllner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carsten Müller-Tidow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Stefanie Göllner or Carsten Müller-Tidow.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Göllner, S., Müller-Tidow, C. AKTing on XPO1 inhibition in AML. Nat Cancer 3, 787–789 (2022). https://doi.org/10.1038/s43018-022-00395-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00395-w

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer